Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Anything goes -- Ignore unavailable to you. Want to Upgrade?

To: LouieD who wrote (4552)	4/5/1998 3:58:00 PM
From: LouieD	Read Replies (2) \| Respond to of 34592

ADDENDUM TO POST #4555...READ THIS! Someone posted this on another thread.It's basically the same info I gave but in greater detail. Speaking of disease (breast cancer) prevention: The Associated Press P H I L A D E L P H I A, April 4 - A drug used for years to treat breast cancer patients has been shown to prevent the disease from even occurring, The Philadelphia Inquirer reported in Sunday's editions, citing a study. The drug tamoxifen cut cancer rates by nearly half among women who were considered at risk of getting the disease, according to a six-year study by the National Cancer Institute, a federal agency that coordinates the nation's cancer programs. The institute recently mailed letters announcing the breakthrough to the 13,000 women in the United States and Canada who participated in the study, the newspaper reported. "This is now the first study in the world to show that a drug can reduce the incidence of breast cancer," the letter stated. Potentially Life-Saving Find The results of the study-one of the largest cancer prevention trials ever undertaken-are to be made public Wednesday. Researchers would not discuss the results with the newspaper. "I'm just thrilled. Wow!" Patricia Lorah, 45, of Reading, told the Inquirer today after receiving her letter. "My mother and grandmother died of breast cancer. This is almost overwhelming." Women at risk of getting the disease because of family history, precancerous breast lesions or age were randomly assigned to five years on either a placebo pill or tamoxifen. The drug, made by Wilmington, Del.-based Zeneca Pharmaceuticals, is widely used to prevent the spread or return of breast cancer. Strong Statistics According to the institute, the drug reduced the rate of expected breast cancers from 1 in 130 women to 1 in 236 during the study, the Inquirer reported. However, tamoxifen also has been associated with increased risks for cancer in the uterine lining and for blood clots in the lungs. Those risks prompted The National Women's Health Network in Washington to criticize the study. "If this turns out to be a good risk-benefit ratio for some women, that will be good news," said Cindy Pearson, executive director of the National Women's Health Network. But it's "imperative for researchers to tell women what.they know about the cost of this benefit. Did any women die of anything caused by tamoxifen?" Tamoxifen slips into estrogen receptors of breast cancer cells and locks up the cells, preventing them from growing and dividing. Controversial Past In 1994, the trial was temporarily suspended during congressional hearings into four uterine cancer deaths in another study of breast cancer treatment using tamoxifen. University of Pittsburgh surgeon Bernard Fisher, coordinator of the prevention trial, also was investigated for reports that he was slow to address research problems. That did not prevent women from staying in the study. "I never considered dropping out. My thoughts were more like, 'Maybe I'll save my child's life and my own and other people's,' " Fern Maklin, 49, of Newtown, told the Inquirer. The participants will be followed for at least two more years. Study Continues Researchers still are analyzing the data and medical recommendations for using tamoxifen to prevent cancer are still being developed, according to the letter. The women now can go to the 270 medical centers participating in the study to find out whether they were taking tamoxifen or the placebo. "I'm hoping I was on tamoxifen, but if I was in the placebo arm, I am going to ask my physician to put me on tamoxifen because I really believe in it," Helen Wilson, 48, of North Wales, told the Inquirer. LouieD

To: LouieD who wrote (4552)	4/5/1998 6:41:00 PM
From: LTK007	Read Replies (1) \| Respond to of 34592

The report just was the headline story on ABC national news.max90

To: LouieD who wrote (4552)	4/5/1998 8:27:00 PM
From: Charliss	Respond to of 34592

Tamoxifen has been out and prescribed for quite a while now. Were you thinking it hadn't been?

To: LouieD who wrote (4552)	4/5/1998 10:58:00 PM
From: Starduster	Respond to of 34592

55,000 woman will die of Breast Cancer this year. Tamoxifen cannot be used on all Breast Cancer patients. It is used on patients with positive hormone receptors. Tamoxifen is a hormone blocker. Tamoxifen is used as adjuvant therapy. It is not a male hormone. It does not have the same side effects often suggested by the words "hormone therapy" you don't grow a beard, or develop a baritone voice. It blocks the estrogen receptor on the breast cancer cell interfering with protein synthesis. The result, shows that it stops the growth of malignant cells dependent on estrogen for growth. It is given as a pill, usually twice a day. Side effects all though minimal may include hot flashes, nausea which usually abates after a month or two and spotting. Other less common side effects include depression, bleeding,loss of appetite and headache. It automatically puts a woman into menapause. This goes on and on. Researchers continue to look for other hormonal drugs with fewer side effects as they monitor the long-range effects of tamoxifen. This puts the patient with negative hormone receptors in a positions of non-use. Good or bad. We don't know yet. Studies not out. The Department of Defense allocated an extra few millions dollars for research in Breast Cancer to save woman's from this dreaded disease. I participated in obtaining those funds. If this stock will split now I believe is the question? I know Zeneca, as they contributed to one of the National Breast Organization's largest fund raiser that I also Co-Chaired this year. Will they split. That's a question I'll have to ask someone in the know. I pray every day for a cure. Unfortunately, 55,000 will die with or without Tamoxifen it cannot be used for all. Lucky Sandie